Creatinine News and Research RSS Feed - Creatinine News and Research

RCC renal function independent of axitinib-induced proteinuria

RCC renal function independent of axitinib-induced proteinuria

Treatment with the vascular endothelial growth factor receptor inhibitor axitinib does not adversely affect renal function in patients with metastatic renal cell carcinoma even in the presence of proteinuria, a Japanese study indicates. [More]
IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL). [More]
Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p). [More]
IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

New IMBRUVICA (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc) during the 56th American Society of Hematology Annual Meeting suggests that IMBRUVICA demonstrates anti-tumor activity both as a single-agent and as combination therapy in heavily pre-treated patients with relapsed or relapsed/refractory multiple myeloma (MM). [More]
Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients. [More]
Alport syndrome: an interview with Dr Paul Grint, CMO, Regulus

Alport syndrome: an interview with Dr Paul Grint, CMO, Regulus

Alport Syndrome was first described by a physician called Cecil Alport, back in the late 1920s. It's a genetic disease that affects a certain type of collagen involved in the functioning of the kidney, the ear, and the eye. [More]
Strict monitoring of lithium levels urged

Strict monitoring of lithium levels urged

Plasma levels of lithium above the advised range are associated with a transient reduction in kidney function, research shows. [More]
D-LIVER project aims to help patients with chronic liver disease

D-LIVER project aims to help patients with chronic liver disease

A European ICT for Health project aims to improve the quality of life of patients with chronic liver disease, by developing a remote support system to monitor their condition at home. [More]
Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen Research & Development, LLC today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA (ibrutinib) to the U.S. Food and Drug Administration by its strategic partner Pharmacyclics, Inc. [More]
Regulus begins ATHENA study to monitor changes in renal function in Alport syndrome patients

Regulus begins ATHENA study to monitor changes in renal function in Alport syndrome patients

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today it has initiated its ATHENA natural history of disease study in patients with Alport syndrome, a life-threatening genetic kidney disease with no approved therapy. [More]
Urinary nerve growth factor shows diagnostic value

Urinary nerve growth factor shows diagnostic value

Urinary nerve growth factor could be a useful biomarker for the diagnosis of overactive bladder and a predictive biomarker to help guide treatment, Chinese researchers believe. [More]
Canada funds 22 inventive ideas for improving health in low-resource countries

Canada funds 22 inventive ideas for improving health in low-resource countries

Grand Challenges Canada, funded by the Government of Canada, today announced $2.4 million in seed funds shared between 22 projects from Canada and nine developing nations, to pursue inventive new ideas for improving health in low-resource countries. [More]
Inflammatory marker signals diabetic nephropathy development

Inflammatory marker signals diabetic nephropathy development

Measuring serum levels of high-sensitivity C-reactive protein could help to predict which patients with Type 2 diabetes will develop renal disease, research suggests. [More]
Lifestyle intervention shows kidney benefits in diabetic patients

Lifestyle intervention shows kidney benefits in diabetic patients

A lifestyle intervention focused on weight loss and increasing physical activity should be considered as additional treatment to prevent advanced kidney disease in overweight or obese people with Type 2 diabetes, say researchers. [More]
FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

ViiV Healthcare announced today that the US Food and Drug Administration has approved Triumeq (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection. [More]
Hypertension control may ward off renal damage in diabetics

Hypertension control may ward off renal damage in diabetics

Elevated blood pressure is associated with an increased risk of renal damage in patients with Type 2 diabetes, especially if they have poor glycaemic control, study findings suggest. [More]
Randox Cystatin C facilitates early detection and treatment of chronic kidney disease

Randox Cystatin C facilitates early detection and treatment of chronic kidney disease

As a more sensitive maker of renal dysfunction Randox Cystatin C offers several advantages over traditional creatinine assays. [More]
Night-time BP variability improves vascular risk prediction

Night-time BP variability improves vascular risk prediction

Measuring night-time variability in the blood pressure of patients with hypertension may help to predict their risk of having a cardiovascular event, show data from an international study. [More]
Standard risk factors stratify already high-risk diabetic patients

Standard risk factors stratify already high-risk diabetic patients

Cardiovascular disease risk factors are associated with mortality even among patients with Type 2 diabetes who are already at high risk due to having high coronary artery calcified plaque, say researchers. [More]
Acute kidney injury and chronic kidney disease are interconnected, say GW researchers

Acute kidney injury and chronic kidney disease are interconnected, say GW researchers

For more than 40 years, physicians have treated diminished kidney function as two distinct syndromes: acute kidney injury (AKI) and chronic kidney disease (CKD). However, recent epidemiologic and mechanistic studies suggest the two syndromes are not distinct entities, but interconnected. [More]